Business
Four Limerick companies secure €17.2 million in first round of Disruptive Technologies Innovation Fund
Minister of State for Trade, Employment, Business, EU Digital Single Market and Data Protection, Pat Breen has congratulated the four Limerick “groundbreaking projects” that have received €17.2 million under the first round of the Disruptive Technologies Innovation Fund.
The successful Limerick projects are:
A consortium including Curran Scientific, Raheen, will receive a maximum of €8.4 million towards a Disruptive Gene Therapy Platform, Replacing Viruses in the Treatment of Genetic Conditions. This project aims to disrupt the Viral Gene Therapy Market using a new Polymer-based Delivery Platform.
HookeBio Ltd is to receive up to €1.9 million as part of the consortium working on the High throughput microfluidic drug screening platform project. The HookeBio platform is a disruptive technology that will allow pharma companies and clinicians to develop more accurate and responsive disease models for drug testing. The platform may be expanded to testing of existing therapies on individual patient’s disease samples.
University of Limerick based Cala Medical is part of a consortium has that has been awarded a maximum of €5 million for the project entitled Therapeutic enzymes as a treatment for sepsis and other immune disorder diseases. This consortium has a disruptive technology, Cytoflow5, for the treatment of sepsis. This technology will be further expanded to disrupt areas currently dominated by monoclonal antibodies and thus disrupt the biologics area. This will result in a panel of new therapies for the treatment of diseases including sepsis, psoriasis, arthritis and Crohn’s disease.